Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of CS-2032 (ChAdOx1-VZV) in Healthy Adults 50-65 Years
NCT05991427Phase 1Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Vaccines & Immunotherapeutics, Adenoviral Vectors
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of CS-2032 in herpes zoster (HZ) (6 arms), sponsored by CanSino Biologics Inc. Primary endpoints: Incidence of local and systemic reactogenicity and Incidence of Serious Adverse Event (SAE) and Adverse Event of Special Interest (AESI). Started Nov 2023; status: completed.
02
Drugs
CS-2032
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT05991427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05991427.